NEW Tobacco Company Publishing Policy
Tobacco Regulatory Science initially (2015) established a policy of not considering tobacco industry research for publication, however, also established a process of annually evaluating that decision. Effective immediately Tobacco Regulatory Science has elected to allow such papers to be considered for publication based on the premise that fair review could be accomplished and a recognition that quality research should be disseminated. Consequently, if you plan on submitting a manuscript and are directly or indirectly funded by the tobacco industry please review here.
NEW Transparency Policy
- Data Access: All authors must agree to make all relevant data and analysis codes available for external review via formal request. If that is not possible, an explanation on why that is not possible must be provided (eg, commercial confidentiality), and will be considered by the Editor-in-Chief when determining whether or not to consider an article for review. It is highly recommended that authors include their data in a repository designed for protection of scientific data in order to assure long term access to those data, study protocols, analytic coding, etc.
- Data Transparency: All authors must confirm that the research design and analysis approach employed in the research met appropriate standards indicated by the Equator Network (https://www.equator-network.org/). Articles that have deviated from those standards can be considered on a case-by-case basis by providing an explanation of that deviation, including how that deviation will be explained in the article.
- Registration of Clinical Trials: All articles that are based on clinical trial data must have been posted in a study registry prior to study implementation, including the analysis plan. Authors must provide the registration organization (eg, ClinicalTrials.gov) and registration number for that trial when submitting the article and will be reviewed by the Editor-in-Chief when determining whether or not to include the article for review. That information will not be provided to reviewers in order to maintain blinded review, but will be included in any articles accepted for publication. Exceptions will be considered on a case-by-case basis by the Editor-in-Chief, and will require a clear rationale that will be stated in the article if it is accepted for publication.
- Article Pre-Review: Authors must indicate whether permission was required by any individual, committee or organizational practice or policy prior to publication, and provide a description of that review and approval process. For example, if there is an organizational requirement that an article be reviewed internally prior to submission, that process must be described, including factors that are considered in that review process.
Manuscripts must conform to the American Medical Association Manual of Style (10th edition). Manuscript title should be concise but informative (do not exceed 75 characters including spaces). Only the first letter of each word in the title should be capitalized – all other letters should be formatted in lower case. The manuscript is in Microsoft Word Windows or Mac, double-spaced, pages numbered, and in a 12-point Times New Roman font.
Original research reports will report new data and include discussions on regulatory implications that best assure linkage and expansion of the science under investigation. The format should be as follows: Abstract, Introduction, Methods, Results, Discussion, Implications for Tobacco Regulation, Human Subjects Approval Statement (when relevant), Conflict of Interest Disclosure Statement, Acknowledgments, References, Tables, and Figures.
The entire abstract should consist of 5 sections (Objectives, Methods, Results, Conclusions, Key words) and not exceed 200 words overall, including all 5 headings. The abstract should state the purpose(s) of the study or investigation, basic procedures, main findings, and the principal conclusions. It should emphasize new and important aspects of the study or observations. Include 4-7 key words or short phrases that will assist in cross-indexing directly after the abstract.
The manuscript should not exceed 5000 words (approximately 18 typed double-spaced pages) excluding the title page, abstract, references, tables, and/or figures. Up to 5 distinct tables and figures (combined) are allowed in total. All pages should be numbered. Where appropriate, indicate use of common methods and measures (see www.PHENX.org). Use Arabic numerals. If the manuscript exceeds these limits, please contact the Editor-in-Chief.
List the sources of support in the form of (1) person(s), grant(s), equipment, or drugs; and (2) note disclaimers, if any, including notices of the manuscript’s prior appearance as a preliminary report, abstract or conference proceedings.
Redact Identifying Information
Redact author or identifying information in text, Acknowledgements or References that identifies author(s) information for reviewing purposes. The redaction should be obscured with a solid black cover. Should the manuscript be accepted, the redaction will be removed.
If using a Reference Management Software similar to EndNote, Mendeley, Zotero, etc. PLEASE REMOVE. Replace with the Numbering format function in Word. The Numbering format function is next to the Bullet format function in the Tool Bar.
References should be numbered consecutively in the order in which they are mentioned in the text using the Numbering format function. No reference should be given more than one number. Identify references in text by superscript Arabic numerals. Avoid using abstracts as references unless it is available in the public domain. References to papers accepted but not yet published should be designated as “in press”; authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should not be cited. Avoid citing a personal communication unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. Authors should obtain written permission and confirmation of accuracy from the source.
Use the style of the examples below. Prepare all the references in AMA style, with the Library of Medicine (NLM) abbreviations for all journals that have them. DO NOT GUESS AT ABBREVIATIONS; USE ONLY THE LEGITIMATE ABBREVIATIONS. If no abbreviation appears in NLM then use the full title of the referenced journal. For assistance with abbreviations go to https://www.ncbi.nlm.nih.gov/nlmcatalog/journals and type in the title of the journal whose abbreviation is being sought. Make sure that the abbreviated journal titles are italicized and that a periods appears at the end of each journal.
Note: All citations listed must be accessible by the reader or it will NOT be allowed.
For secondary sources, direct quotations, and citations from books or reports, give specific page numbers. Remember; cite personal communications in text only, giving the source and date. If communication is an email: provide sender’s address. References should be listed in the following manner:
Journal Publications of up to 4 Authors (list all 4)
Mumford EA, Pearson JL, Villanti AC, Evans WD. Nicotine and e-cigarette beliefs and policy support among US smokers and nonsmokers. Tob Regul Sci. 2017;3(3):293-304.
Publications of more than 4 Authors (list only 3 followed by et al.)
Russo AR, Solis AC, Villanti AC, et al. Mentoring success in tobacco regulation science: a qualitative study. Tob Regul Sci. 2017;3(3):280-292.
US Food and Drug Administration. Preliminary Scientific Evaluation of the Possible Public Health Effects of Menthol versus Nonmenthol Cigarettes. Silver Spring, MD: Center for Tobacco Products, Food and Drug Administration; 2013.
Quoted Chapter in Books
Eriksen M and Whitney C. Risk Factors: Tobacco. In McQueen DV, Global Handbook on Noncommunicable Diseases and Health Promotion. New York: Springer. 2013, pp 115-136.
Bruce Ballantine. EPC WORKING PAPER N° 17: Enhancing the role of science in the decision-making of the European Union. European Policy Centre; 2005 (March):1-49.
Example of Online Journal Article with a DOI
Katz SJ, Weijia S, Erkkinen M, et al. High school youth and e-cigarettes: the influence of modified risk statements and flavors on e-cigarette packaging. Am J Health Behav. 2020:44(2):130-145. doi: org/10.5993/AJHB.44.2.2
Example of Online Journal Article with URL
Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics. 1986;77(4):471-476. https://pubmed.ncbi.nlm.nih.gov/3960615/. Published November 1, 2013. Accessed November 12, 2019.
Number figures consecutively in the order of their first citation in the text. Letters, numbers, and symbols should be clear and even throughout and of sufficient size that each item will still be legible when reduced for publication. Titles and detailed explanations belong in the legends for figures, not embedded in the figures themselves. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. Permission is required irrespective of authorship or publisher, except for documents in the public domain. Be sure each figure is cited in text and note where you believe the figure should be placed.
Number of Figures Allowed
Each published paper is allowed up to 6 tables and/or figures (any combination of tables or figures adding to 6) at no additional cost. Because an increasing number of authors have requested to include additional figures beyond the number allotted in these guidelines, we have instituted an additional fee to cover the costs of editing and typesetting figures. To peruse fees, click here.
Insert each table, double-spaced, on a separate page. Number tables consecutively in the order of their first citation in the text and supply a brief but stand-alone title for each. Be sure each table is cited in text and note where the table should be placed. Do not use internal horizontal and vertical lines to create tables, you must use the table function in Word to create the table. Use Note section to explain all abbreviations or data descriptions used in each table in alphabetical sequence: a, b, c, d, e, etc. Do not use superscripted numbers (1, 2, 3, etc), symbols or asterisks to identify items in the table. Asterisks are only use to identify p values. If you use data from another published or unpublished source, obtain permission and acknowledge it fully.
Tables should be on separate pages and appear at the end of the manuscript after the references. Each portrait table width should not exceed 7 inches (18 cm) or 8 columns using 12-point Times New Roman font. Each landscape table width should not exceed 9 inches (23 cm) or 10 columns using 12-point Times New Roman font. Do not embed titles into the table. Do not submit images of tables in TIFF, PNG, JPEG or PDF formats. Use the Table function in Word to create the table. If unsure the table is acceptable, please e-mail the journal offices and send the proposed table for review prior to submission.
Number of Tables Allowed
Each published paper is allowed up to 6 tables and/or figures (any combination of tables or figures adding to 6) at no additional cost. Because an increasing number of authors have requested to include additional tables beyond the number allotted in these guidelines, we have instituted an additional fee to cover the costs of editing and typesetting tables. To peruse fees, click here.
Up to 3 published pages of supplementary materials/appendices allowed at no additional cost. Typically, 2 double-spaced typewritten pages and/or supplementary tables or figures equaling 2 pages is equivalent to 1 page in the journal of supplementary materials/appendices. Consequently, 6 pages of double-space supplementary materials/appendices (includes tables and figures submitted as supplementary materials) is allowed. Because an increasing number of authors have requested to include additional supplementary material/appendices beyond the number of pages allotted in these guidelines, we will now institute an additional fee to cover the costs of editing and typesetting tables, figures and supplementary material/appendices that exceed the journal guidelines. To peruse fees, click here.
All submitted supplementary materials will be converted to “published papers.”
Options to Excessive Tables, Figures, or Supplementary Materials/Appendices
- Accept the fee(s) for additional table(s), figure(s) or supplementary materials/appendices
- Reduce the table(s), figure(s) and supplementary material(s)/appendice(s) to required amount (no charge)
- Provide a link in the paper that leads readers to the table(s), figure(s) or supplementary material(s)/appendice(s) on your own web site (no charge)
- Provide your email with the instructions that if they wish to secure copies of the additional tables(s), figure(s) or supplementary materials readers contact you (no charge).
Abbreviations and Nomenclature
Abbreviations and nomenclature should conform to the American Medical Association Manual of Style (10th edition). Abbreviations should be kept to a minimum in the text and should be defined at first usage. Periods are not used after abbreviations (eg, mm, mL). Generic names are preferred for drugs.
Develop a Press Review
Should your manuscript be accepted and published in the journal, you will be provided assistance whereby you can develop a press release to further promote your research.
If additional questions arise, feel to contact the journal offices.
Ethical Guidelines for Publications
Tobacco Regulatory Science adheres to the COPE Core Practices regarding ethical guidelines for publication. In addition, we support use of the Transparency and Openness Promotion (TOP) guidelines regarding journal policies and practices. Included in the COPE and TOP practices are the following:
- Allegations of Misconduct. Any allegations of scientific misconduct should be immediately brought to the attention of the Editor-in-Chief, and those allegations will be addressed according to COPE standards.
- Authorship. Listed authors on a manuscript should have made significant contributions to justify their inclusion according to guidelines established by the AMA Manual of Style, 10th Edition, including significant roles in study design, data analysis, study implementation, interpretation of results and paper write-up. Authorship roles should be able to be justified if asked by reviewers or editorial staff. Any concerns about authorship will be addressed according to COPE standards.
- Complaints or Appeals. Any complaints or concerns about any aspect of the publication process should be directed to the Editor-in-Chief or the Executive Editor.
- Conflict of Interest Disclosure Statement. Preventing and addressing real or potential conflicts of interest are essential to assuring confidence in study results and is taken very seriously by the editorial staff and reviewers alike. COPE guidelines are followed, with more specific information requested of all authors on the current Tobacco Regulatory Science website:
Articles published in Tobacco Regulatory Science must be accompanied by a conflict of interest disclosure statement, or a statement that authors have no conflicts of interest to declare (All authors of this article declare they have no conflicts of interest). To execute this policy, all authors must privately disclose to the editors of Tobacco Regulatory Science at the time of their submission ANY and ALL potential conflicts of interest. These include financial and non-financial interests and relationships (see below for definitions), direct employment with a private sector entity (whether full-time, part-time, or on a consultancy basis), and service on private sector and non-profit boards and advisory panels, whether paid or unpaid. Authors also should disclose to editors any conflict of interest that may have influenced either the conduct or the presentation of research, including but not limited to close relationships with those who might be helped or hurt by the publication, academic interests and rivalries, and any personal, religious or political convictions relevant to the topic at hand. In the paper, authors should include a draft statement that discloses all relevant conflicts of interest and affiliations. Relevance for financial conflicts of interest with private firms is defined as a relationship of any value with a firm with a stake in the subject of the manuscript, or its competitors. Relevance for patents is defined as any invention or pending invention connected in any way to one of the authors. Because relevance is often “in the eye of the beholder,” err on the side of full disclosure in drafting the disclosure statement. Editors will check your draft against the private financial disclosure statement, and initiate discussions toward possible adjustments, if necessary.
What to report: Any financial relationship from the past 3 years (dating from the month of submission) of any size should be disclosed. These potential conflicts of interest include:
- Direct employment, either full or part-time;
- Grants and research funding (but not grants to your institution or others within your institution on which you did not work); this includes grants from trade associations and non-profits substantially (50% or more) funded by private-sector firms;
- Travel grants, speaking fees, writing fees, and other honoraria;
- Paid expert testimony for one side in an adversarial proceeding (this does not include testimony as a factual witness in a civil or criminal case);
- Patents granted, pending and applications, whether or not generating royalties;
- Stock ownership, investment in related “sector” funds, or stock options, including those of immediate family members but excluding diversified mutual funds and investment trusts; and
- Membership on private sector scientific or other advisory boards, whether paid or unpaid.
In addition, any current negotiations regarding future employment or current job offers, either full-time or part-time, must be disclosed.
In disclosing these financial arrangements to editors, authors can include dollar amounts even though they will not be printed in the journal. Editors may choose to exclude this information from publication, but in no case should an editor or author consider an arrangement irrelevant based on its size alone.
Non-Financial Conflicts of Interest: Authors may have strongly-held views about the article being submitted for publication. Authors should consider disclosing and editors may choose to print any affiliations or expressions of these views that may be relevant. These may be personal, political, or intellectual and may include any expression of strongly held views relevant to the subject of the submission. Such disclosures may be original, or they make reference to opinions previously expressed in books or monographs, op-eds or public comments, or to sworn testimony before or lobbying of legislators or legislative bodies. Non-financial conflicts of interest that should be disclosed also include membership or affiliation with non-governmental organizations that have an interest in the submission.
Enforcement: Conflict of interest disclosure relies on the honor system. Editors do not have the time or other resources to be financial auditors or ideological arbiters. Successful disclosure policies depend on the good will and integrity of authors. In all cases of failure to disclose a relevant conflict of interest of which the editors become aware; they will publish an editor’s note that becomes part of the permanent record of that article. In those rare cases where editors uncover a willful desire to conceal financial conflicts of interest, the editors will disallow publication by the author(s) in Tobacco Regulatory Science for a period of up to 3 years.
- Data and Reproducibility. All studies that report data from a clinical trial must indicate whether or not they have preregistered their study (eg, clinicaltrials.gov). If so, trial number should be included in the paper. It is strongly recommended that all clinical trials be registered.
- Ethical Oversight. Tobacco Regulatory Science will follow the COPE protocol if there are concerns about ethical concerns regarding a submission, and the following protocols are required of all submissions involving human or animal research.
a. Human Subjects or Animal Approval Statement.
i. Where relevant, include human subjects or animal protection statements indicating institutional review and approval with document number, if possible, or statement of exempt status. More specifically, all studies involving humans should indicate that they meet the ethical standard outlines in Helsinki Declaration of 1975 as revised in 2000, and studies involving animals should indicate that they meet the National Research Council requirements on the Care and Use Laboratory Animals.
b. Informed Consent Requirement
i. Where appropriate, and consistent with institutional review board requirements, Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), European Union Directive 95/46/EC, and other rules specific to the location of where the research was conducted, include a clear indication that informed consent was obtained from all participants in the research.
c. Plagiarism Prevention Process.
i. Prior to submission, all manuscripts are expected to have been checked for unattributed text via one of several automated software programs (eg, Grammarly, Plagiarisma, PaperRater, iThenticate, etc).
- Intellectual Property. Policies regarding copyright and copyright violations are available on the journal website and other journal practices and policies.
It is the responsibility of the author or authors to obtain the necessary permission to use any quoted material in excess of 25 lines that is incorporated in the manuscript. Permission must be obtained, and credit given, for quotations, tables, and illustrations borrowed from copyrighted material. Letters granting permission should accompany the manuscript when submitted. If there are any questions, contact the Editor-in-Chief or the Executive Editor.
- Journal Management. The journal is owned by the Executive Editor, Editor-in-Chief and Business Manager. A group of senior scientists in the field serve as Senior Associate Editors (SAE); moreover, advice is sought from the SAE panel as needed. In addition, scientists and experts regarding tobacco regulatory science serve as Associate Editors (AE), and their primary role is to serve as reviewers for the journal. Additional information can be found on the journal website.
- Peer Review Processes. To decrease bias during the editorial process, we employ the classic double-blind peer review process. Referees selected are professional scholars in a variety of disciplines including social and behavioral health sciences, health policy, epidemiology, psychology, chemistry, genetics, neuroscience, and other areas relevant to tobacco regulatory science.
- Upon receipt, a manuscript is assigned a reference number.
- A copy of the numbered manuscript is electronically sent to a minimum of 3 referees.
- Referees are selected to match the manuscript with the referee’s area of expertise.
- Referees evaluate the manuscript according to established criteria on an evaluation form.
- The Editor-in-Chief transmits reviewer evaluations and comments to the corresponding author, usually within 4 weeks.
- Final disposition of the manuscript rests with the Editor-in-Chief.
- Post Publication Discussions and Corrections. Tobacco Regulatory Science includes the option for commentary regarding published articles by submitting a Letter to the Editor. The process for doing so is described on the journal website. In addition, if post-publication corrections are needed, please contact the Executive Editor to determine what corrections can be made. There are no charges to correcting proofs, however, once the manuscript is posted online (post publication) there is a fee for any changes, and that fee will depend on the type and extent of change needed.
Revised June 29, 2020